Päivi Östling

A human-supervised multi-agent LLM system covered drug repurposing from knowledge graph building to assay analysis in three case studies; retrospective COVID-19 screen AUC-ROC 0.986 without predefined thresholds.

The paper presents a cost-effective workflow combining multiplexed immunofluorescence and in situ proximity ligation assay to detect protein interactions and cell types in clinical samples.

The paper identifies host-targeting antivirals against SARS-CoV-2 using morphological profiling, finding compounds that reverse infected cell phenotypes and validate host processes hijacked by viruses.

The paper develops a machine learning model to predict drug-induced phospholipidosis using a large dataset of repurposed drugs tested across multiple cell lines.

This paper introduces DIPx, a model predicting drug synergy using pathway activation scores, showing better performance than existing methods on both known and novel drug combinations.

This study shows SMAC mimetics overcome apoptotic resistance in ovarian cancer by targeting the MSLN-TNF alpha axis, enhancing cell death and synergizing with chemotherapy.